Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Advertisement

Close

AACR Journals
For Authors
About Us
Article Collections
COVID-19
Webinars

header search

search input Search input auto suggest

Search

Advanced Search

Menu

About
Articles
First Disclosures
For Authors
Alerts
News
COVID-19
Webinars

Skip Nav Destination

Current Issue

Volume 21,

Issue 5

1 May 2022

View This Issue

About the Journal

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug action, mechanism of drug resistance, biomarkers of drug response, novel models and technologies, and occasional drug toxicity mechanisms.. Read More About the Journal

Editor-in-Chief

Beverly A Teicher

View Full Editorial Board

Impact Factor

6.261

SUBMIT TO JOURNAL

Featured Articles

Research Article

Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies

O’Brien et al.

Research Article

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma

Javaid et al.

Research Article

Proteolytic pan-RAS cleavage leads to tumor regression in patient-derived pancreatic cancer xenografts

Vidimar et al.

Trending - Altmetric

Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β

Last mentioned on Saturday May 21 2022

Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells

Last mentioned on Saturday May 21 2022

Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor

Last mentioned on Friday May 20 2022

HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor

Last mentioned on Friday May 20 2022

Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma

Last mentioned on Friday May 20 2022

Latest
Most Read
Most Cited

Targeting DUSP activity as a treatment for high grade serous ovarian carcinoma

GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis

Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non–Muscle Invasive Murine Bladder Cancer

PLGA-nano-encapsulated Disulfiram inhibits hypoxia-induced NFκB, cancer stem cells and targets glioblastoma in vitro and in vivo

Tweets by MCT_AACR

Issues
Online First
News

Twitter

Online ISSN 1538-8514
Print ISSN 1535-7163

AACR Journals

Blood Cancer Discovery
Cancer Discovery
Cancer Epidemiology, Biomarkers, & Prevention
Cancer Immunology Research
Cancer Prevention Research
Cancer Research
Cancer Research Communications
Clinical Cancer Research
Molecular Cancer Research
Molecular Cancer Therapeutics

Info for Advertisers
Info for Librarians
Privacy Policy

Twitter
LinkedIn
Facebook
Youtube

Copyright © 2022 by the American Association for Cancer Research.

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.

Accept